Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aventis And Chiron Developing Avian Flu Vaccine For NIH Clinical Trials

Executive Summary

The National Institute of Allergy & Infectious Diseases has contracted rival flu vaccine manufacturers Aventis and Chiron to develop an investigational avian flu vaccine

You may also be interested in...



Pediatric Flu Vaccine Formulation Should Be Developed, Advisory Cmte. Says

A pediatric flu vaccine containing two influenza B strains should be developed, members of the FDA's Vaccines & Related Biological Products Advisory Committee recommended

Pediatric Flu Vaccine Formulation Should Be Developed, Advisory Cmte. Says

A pediatric flu vaccine containing two influenza B strains should be developed, members of the FDA's Vaccines & Related Biological Products Advisory Committee recommended

Vaccine Market Transition: Flu Pandemic, Stockpile Plan May Drive Production

HHS is seeking to increase influenza vaccine production capacity through financial incentives in the form of higher governmental demand

Related Content

UsernamePublicRestriction

Register

PS044058

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel